A Phase III open-label, randomized, multicenter study of imprime pgg in combination with cetuximab in patients with kras wild type metastatic colorectal cancer

View/Open

4288729.pdf (71.37Kb)

Author

Meyerhardt, Jeffrey A

Grady, Michele M

Lowe, Jamie N

Gargano, Michele A

Huhn, Richard D

Braun, Ada H

Published Version

https://doi.org/10.1186/2051-1426-2-S3-P71

Metadata

Show full item record

Citation

Meyerhardt, Jeffrey A, Michele M Grady, Jamie N Lowe, Michele A Gargano, Richard D Huhn, and Ada H Braun. 2014. “A Phase III open-label, randomized, multicenter study of imprime pgg in combination with cetuximab in patients with kras wild type metastatic colorectal cancer.” Journal for Immunotherapy of Cancer 2 (Suppl 3): P71. doi:10.1186/2051-1426-2-S3-P71. http://dx.doi.org/10.1186/2051-1426-2-S3-P71.

Other Sources

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288729/pdf/

Terms of Use

This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA

Citable link to this page

http://nrs.harvard.edu/urn-3:HUL.InstRepos:13890586